Global Blood Therapeutics, Inc. Banner Image

Global Blood Therapeutics, Inc. has reached its limit for free report views

Work for Global Blood Therapeutics, Inc.? Upgrade Your Profile and unlock all your annual reports.

Global Blood Therapeutics, Inc.

  • Ticker GBT
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Global Blood Therapeutics, Inc. Logo Image
  • 201-500 Employees
  • Based in South San Francisco, California
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introducedMore Oxbryta® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a p-selectin inhibitor in development to address pain crises associated with the disease. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD.
Global Blood Therapeutics, Inc.

Most Recent Annual Report

Global Blood Therapeutics, Inc. MOST RECENT 2019 Annual Report and Form 10K

Report Locked. Global Blood Therapeutics, Inc. has reached its limit for free report views.

Older/Archived Annual Reports